在携带MTHFR多态形态的糖尿病视网膜病患者中对Ocufolin®的血型血管标记反应
Jianhua Wang1, Andrew Hoover1,2, Justin H Townsend1
1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, FL, USA.
Biomarker insights
|September 29, 2025
概括
用Ocufolin®补充叶酸改善了2型糖尿病和糖尿病视网膜病变患者的关键血清标志物. 这表明通过使叶酸代谢正常化来管理血管并发症的潜在好处.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 眼科医生 眼科 眼科
背景情况:
- 甲基基酸减少酶 (MTHFR) 基因变异与代谢错误有关,增加了糖尿病视网膜病变中的微血管风险.
- 早期的营养干预,特别是叶酸补充剂,可以稳定新陈代谢,在不可逆转的损伤之前减缓疾病的进展.
研究的目的:
- 评估叶酸补充剂Ocufolin®对2型糖尿病 (T2D) 轻度糖尿病视网膜病变 (MDR) 患者血清生物标志物的影响.
主要方法:
- 一项前性队列研究涉及10名患有MDR和MTHFR多态形态的T2D患者,他们接受了Ocufolin®.
- 血清生物标志物,包括同类半素,hs-CRP,VEGF和其他被测量干预前后.
主要成果:
- 奥库福林®治疗导致同类半素,hs-CRP,禁食胰岛素和VEGF的显著降低.
- D-Dimer水平增加,而谷氨和MPO显示了适度的变化. 而HbA1c则保持不变.
结论:
- 通过使叶酸代谢正常化,Ocufolin®有效地改善了糖尿病视网膜病变患者的关键血液生物标志物.
- 这些改进表明,通过增强的视网膜输液和减少氧化应激,在治疗血管视网膜病变方面可能具有辅助治疗作用.
关键词:
B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12在CRP中使用CRP.L-甲基叶酸盐的使用方法在MTHFR的基础上.糖尿病视网膜病变 糖尿病视网膜病变葡萄糖氨酸是什么 葡萄糖氨酸同型半氨酸同型半氨酸更多相关视频
相关概念视频
Blood Types
18.2K
Human blood is classified into different types based on the presence of antigens on the red blood cell's surface and antibodies in the plasma. Proper identification of blood type is essential for successful blood transfusion. The International Society of Blood Transfusion has identified 38 human blood types based on the surface antigens on the red blood cells. The most common types are ABO, Rh, and MNS blood types.
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
18.2K
Blood Transfusion and Agglutination
13.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
100
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Diabetic Retinopathy
65
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
65


